News

In the News part you can find Company Announcements, press releases and Online news as downloadable PDF files in English and Danish.

Company Announcements

RSS feed - Stock Exchange Announcements

Increased operating profit by 18% in the first quarter of 2013 (1 May 2013)

Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 February 2013)

Novo Nordisk increased operating profit by 32% in 2012 (31 January 2013)

Tresiba® and Ryzodeg® receive marketing authorisations in Europe (21 January 2013)

Ryzodeg® (insulin degludec/insulin aspart) approved in Japan (25 December 2012)

Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan (3 December 2012)

Novo Nordisk increased operating profit by 34% in the first nine months of 2012 (31 October 2012)

Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities (19 October 2012)

Novo Nordisk increased operating profit by 31% in the first half of 2012 (9 August 2012)

Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 (27 April 2012)

Novo Nordisk increased operating profit by 18% in 2011 (2 February 2012)

Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes (7 November 2011)

Novo Nordisk A/S: Interim financial report for the period 1 January 2011 to 30 September 2011 (27 October 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US (29 September 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe (26 September 2011)

Novo Nordisk increased operating profit by 27% in 2010 (2 February 2011)

Interim financial report for the period 1 January 2010 to 30 September 2010 (28 October 2010)

Interim financial report for the period 1 January 2010 to 30 June 2010 (5 August 2010)

Interim financial report for the period 1 January 2010 to 31 March 2010 (27 April 2010)

Press Releases

RSS feed - Press Releases

Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen (18 September 2014)

Mexico first country to launch Ryzodeg® (1 September 2014)

Novo Nordisk accepts fine for violating disclosure obligation in Denmark (18 August 2014)

Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation (10 December 2013)

Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 (3 December 2013)

New study demonstrates efficacy throughout 2.5 years for Tresiba® (24 September 2013)

Study confirms improved health-related quality of life for patients with type 2 diabetes receiving Tresiba® (22 June 2013)

Featured stories

RSS feed - Featured stories

No results matching your criteria

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •